Tirzepatide (Mounjaro) a dual GLP-1/GIP agonist licensed in the UK for type 2 diabetes and, following a positive NICE technology appraisal (TA1026), recommended for weight management in eligible adults within specialist services
Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials
All three receptor pathways are now operating at high capacity
Retatrutide 10mg (Canada) Lyophilized research material supplied in a sealed 3 mL vial for laboratory research and analytical evaluation only
One such treatment is retatrutide, which is currently undergoing clinical research to evaluate its effectiveness within structured, medically supervised weight management programs
Prioritize Sleep Dont underestimate the power of good sleep for weight control
